Dr Mitchell Sanders, the CEO and Founder of ECI Biotech, highlighted ECI Biotech’s role as a premier developer and manufacturer of innovative, patented ExpressDetect diagnostic technology that enables rapid, easy detection of microbial pathogens. The ExpressDetect sensors that ECI Biotech has developed are low cost, rapid, safe, and simple enough for incorporation into a variety of products that can provide rapid infection diagnostics for use in professional as well as consumer OTC markets.

ECI Biotech's product pipeline includes a diagnostic sensor for urinary tract infections, as well as advanced wound care systems that provide early warning of emergent infections and promote healing. The dressing sensor is simple enough to see a food grade blue color collect on the surface of the dressing, inexpensive enough that the components cost less than ten cents, generally regarded as safe (GRAS) to go on your skin or in a wound, and rapid enough to change color in 30 minutes to an hour.

The Life Sciences Venture Forum, produced by Larta Institute for the past 14 years, is a marketplace for innovation where cutting-edge solutions are presented by vetted seed and early stage companies. The Forum's presenting companies are rigorously selected by Larta's Selection Committee, which includes industry leaders and experts from across the United States. Entrepreneurs are drawn from top tier NIH-funded startups, university spinouts, and discoveries from overseas.

Innovations and Applications

ECI Biotech’s executive offices and research facilities are located at 85 Prescott Street, in Worcester, Massachusetts. ECI Biotech is a leading edge protein sensor company with strong intellectual property of particular value for diagnostic sensors and therapeutics. Founded in 1998, its technologies relate to the detection of microbial pathogens and stabilising active proteins to protect against infection.

ECI Biotech has four areas of core competence: molecular biology, genomics, protein expression, and assay development. ECI’s target markets for its products include: feminine care, wound care, oral care, and hospital infection control.

ECI Biotech's product pipeline includes a diagnostic sensor for urinary tract infections, as well as advanced wound care systems that provide early warning of emergent infections and promote healing. ECI presently has corporate partnerships with medical device industry leaders, and has 18 patents pending and three patents issued.